Cardiac Biomarkers Market Overview, Size, Industry Share, Growth, Forecast 2024-2032

The latest report by IMARC Group, titled “Cardiac Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2032,” offers a comprehensive analysis of the cardiac biomarkers market report. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry.

The global cardiac biomarkers market size reached US$ 10.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.6% during 2024-2032.

Cardiac biomarkers are substances released into the blood when the heart is damaged or stressed, serving as indicators for various cardiovascular conditions. These biomarkers are crucial for diagnosing and managing heart conditions such as myocardial infarction (heart attack) and heart failure. These biomarkers, including troponin, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP), are characterized by their high specificity and sensitivity in detecting cardiac events.

They possess properties such as rapid release into the bloodstream following cardiac injury, measurable concentration changes correlating with the extent of damage, and the ability to provide real-time information about the heart's condition. The advantages of using cardiac biomarkers include early and accurate diagnosis, guiding treatment decisions, monitoring disease progression, and improving patient outcomes by enabling timely and targeted interventions.

Request to Get the Sample Report: https://www.imarcgroup.com/cardiac-biomarkers-market/requestsample

Market Trends:

The global market is majorly driven by the rising prevalence of cardiovascular diseases (CVDs) worldwide. With an increase in lifestyle-related conditions such as obesity, diabetes, and hypertension, the incidence of heart diseases is climbing. This growing burden of cardiovascular conditions necessitates accurate and timely diagnostic tools, thereby bolstering the demand for cardiac biomarkers. Furthermore, technological advancements in biomarker detection and analysis are also significantly propelling market growth. Innovations such as high-sensitivity assays, point-of-care testing devices, and advanced laboratory techniques facilitating early detection, precise diagnosis, and effective management of heart-related conditions are also impelling the market.

With advancements in genomics and proteomics, there is a growing emphasis on tailoring treatments based on individual biomarker profiles. This shift towards personalized care is fueling demand for cardiac biomarkers that can provide detailed insights into an individual's cardiovascular health and response to treatment. Besides, the aging global population contributes to market growth. As individuals age increases, their risk of developing cardiovascular diseases rises, creating a greater need for diagnostic and monitoring tools like cardiac biomarkers. This demographic shift exhibits the importance of effective heart disease management and drives demand for biomarkers. In addition, increased healthcare expenditure and advancements in healthcare infrastructure, particularly in emerging economies, are enhancing access to cardiac biomarker testing, which is creating lucrative opportunities in the market.

View Full Report with TOC & List of Figure: https://www.imarcgroup.com/cardiac-biomarkers-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

• Abbott Laboratories
• Alere Inc.
• Beckman Coulter
• Becton
• Dickinson And Co.
• Biomerieux
• Bio-Rad Laboratories
• Randox Laboratories
• Roche Diagnostics Corporation
• Siemens Healthcare
• Thermo Fisher Scientific

Cardiac Biomarkers Market Segmentation:

Our report has categorized the market based on region, type, location of testing, and application.

Breakup by Type:

• Troponins (T and I)
• Myocardial Muscle Creatine Kinase (CK-MB)
• Myoglobin
• Brain Natriuretic Peptide (BNPs) or NT-proBNP
• Ischemia Modified Albumin (IMA)
• Others

Breakup by Location of Testing:

• Laboratory Testing
• Point of Care Testing

Breakup by Application:

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Others

Regional Insights:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:

• Market Performance (2018-2023)
• Market Outlook (2024-2032)
• Porter’s Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145